Learning Objectives. Page 1
|
|
- Marion Watts
- 5 years ago
- Views:
Transcription
1 Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in the discovery of actionable mutations in DDR (e.g., BRCA1/2) and the developments in precision medicine targeting these mutations, including poly (ADP-ribose) polymerase (PARP) inhibitors. 3. Assess current guideline recommendations for genetic testing and counseling in patients with possible or known pathogenic DNA damage response mutations. 4. Using a case-based approach, evaluate challenging questions encountered in the genetic testing and counseling of BRCA1/2 and other DDR mutations and discuss the evolving role of the genetic counselor in the interprofessional oncology care team. Page 1
2 Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 10, All materials contained herein reflect the views of the faculty, and not those of Creative Educational Concepts, Inc. or the commercial supporter(s). Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for specific patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient s conditions and possible contraindications on dangers in use, review or any applicable manufacturer s product information, and comparison with recommendations of other authorities. Usage Rights: This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts, Inc. Additional terms and conditions may apply. BRCA and Beyond Identifying Genomic Targets in DDR and the Emergence of Precision Medicine in Cancer Nadine M. Tung, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Page 2
3 Pathways DNA Damage Repair PARPi BRCA1/2 Platinum Lynch MSI BER=base excision repair; HR=homologous recombination; MMR=mismatch repair; MSI=microsatellite instability; NER=nucleotide excision repair; NHEJ=non-homologous end joining Cervelli T. Int J Mol Sciences Pathways DNA Damage Repair PARPi BRCA1/2 Platinum Lynch MSI Cervelli T. Int J Mol Sciences Page 3
4 Relative Risk BRCA1/2 Repair Double Strand Breaks in DNA Homologous Recombination (FA-BRCA) ATM BRCA2 BRCA1 CHEK2 PALB2 FA=Fanconi anemia Pennington KP, et al. Gynecol Oncol Breast Cancer Susceptibility Genes RR >5 High Clinical SNPs/PRS RR <2 Low risk: GWAS RR 2 5 Moderate PRS=polygenic risk scores; Minor Allele Frequency (%) SNP=single-nucleotide polymorphism; GWAS=genome-wide association study Foulkes WD. N Engl J Med Page 4
5 Gene Mutations Associated with a Hereditary Predisposition to Breast Cancer High penetrance (RR >5; Lifetime Risk >40%) Gene Syndrome Breast Cancer Risk (to 70) BRCA1 Breast-ovarian 57% 87% BRCA2 Breast-ovarian 57% 87% TP53 Li-Fraumeni >90% PTEN Cowden Syndrome 25% 50% STK11/LKB1 Peutz-Jeghers 45% 54% CDH1 Diffuse gastric cancer 39% Robson M. N Engl J Med. 2007; Graffeo R, et al. Breast Cancer Res Treat Breast Cancer Risk with Moderate Risk Genes Gene Breast PALB2 Y (RR 5.3) ATM Y (RR 2.8) CHEK2 (truncating) Y (RR 3.0) NBN Y (RR 2.7) NF1 Y (RR 2.6) BRIP1 RAD51C RAD51D BARD1 No evidence No evidence No evidence Insufficient evidence High Risk Easton DF, et al. N Engl J Med. 2015; Pelttari LM, et al. Hum Mol Gen. 2011; Meindl A, et al. Nat Gen. 2010; Couch FJ, et al. JAMA Oncol. 2017; Loveday C, et al. Nat Genet. 2011; Loveday C, et al. Nat Genet. 2012; Pelttari LM, et al. J Med Genet. 2012; Kurian AW, et al. JCO Pres Oncol. 2017; Easton DF, et al. J Med Genet. 2016; Weber-Lassalle N, et al. Breast Cancer Res. 2018; Couch FJ, et al. J Clin Oncol. 2015; NCCN Breast/Ovarian Genetic Assessment Guidelines, v Page 5
6 Risk of Breast Cancer Associated with Inherited Mutations High penetrance Moderate penetrance Gene Breast Cancer Risk (by age 70) BRCA1 57% 87% BRCA2 57% 87% PALB2 33% 58% ATM 20% 30% CHEK2 20% 30% Antoniou AC, et al. N Engl J Med. 2014; Tung N, et al. Nat Rev Clin Oncol. 2016; Graffeo R, et al. Breast Cancer Res Treat Breast Cancer Risk Estimates Affected by Family History Even true for BRCA1/2 Higher risks for breast or ovarian cancer for carriers with strong family history PALB2 35% risk of breast cancer by age 70 33% (no family history) and 58% (2 first-degree relatives diagnosed by age 50) Antoniou AC, et al. N Engl J Med Page 6
7 Mutation-Specific Risks Risks still emerging; may depend on type of mutation more than on highrisk genes CHEK2 Frameshift mutations: 1100delC (RR ) Missense mutations: I157T (470 T>C) and S428F (1283 C>T): lower risks (RR 1.5) ATM Some missense mutations: high risk of breast cancer ATM c.7271t>g; RR Easton DF, et al. N Engl J Med. 2015; Han FF, et al. DNA Cell Biol. 2013; Goldgar DE, et al. Breast Cancer Res. 2011; Southey MC, et al. J Med Genet. 2016; Tung N, et al. Nat Rev Clin Oncol Risk of Ovarian Cancer Gene Estimated Lifetime Risk of Ovarian Cancer Recommended Age for RRSO BRCA1 31% 59% BRCA2 18% 34% by age 45 BRIP1 13% >45 RAD51C 6% >45 RAD51D 14% >45 PALB2 2.3% 11%? Unknown or insufficient evidence BARD1 Insufficient data? (OR 4.2) Unknown or insufficient evidence NCCN Breast/Ovarian Genetic Assessment Guidelines v1.2018; Hartmann LC, et al. N Engl J Med. 2016; Antoniou AC, et al. N Engl J Med. 2014; Norquist BM, et al. JAMA Oncol. 2016; Ramus SJ, et al. J Natl Cancer Inst. 2015; Song H, et al. J Clin Oncol. 2015; Chen S, Parmigiani G. J Clin Oncol. 2007; Mavaddat N, et al. J Natl Cancer Inst Page 7
8 Cancer Risks with Novel Genes Gene Breast Ovary Other PALB2 Y (RR 5.3)? (RR ) Pancreas ATM Y (RR 2.8) Pancreas CHEK2 (truncating) Y (RR 3.0) Colon NBN Y (RR 2.7) NF1 Y (RR 2.6) NF1-related BRIP1 N Y (RR ) RAD51C Insuff data Y (OR 5.2) RAD51D Insuff data Y (OR 12) BARD1 Insuff data (TNBC)? (OR 4.2) Easton DF, et al. N Engl J Med. 2015; Antoniou AC, et al. N Engl J Med. 2014; Couch FJ, et al. J Clin Oncol. 2015; Norquist BM, et al. JAMA Oncol. 2016; Ramus SJ, et al. J Natl Cancer Inst. 2015; Song H, et al. J Clin Oncol. 2015; NCCN Breast/Ovarian Genetic Assessment Guidelines v Tung N, et al. Nat Rev Clin Oncol Page 8
9 Why Do Genetic Testing of a Cancer Patient? Identify other cancers to screen for or to prevent Family members Treatment Platinum chemotherapy PARP inhibitors Tumors in BRCA Carriers Cancers in BRCA carriers cannot repair DS DNA breaks Any therapy (platinum or PARPi) that increases the number of DS DNA breaks in the tumor may lead to cell death DS=double strand Cervelli T. Int J Mol Sciences Page 9
10 Pathways DNA Damage Repair PARPi BRCA1/2 Platinum Lynch MSI Cervelli T. Int J Mol Sciences Pathways DNA Damage Repair PARPi BRCA1/2 Platinum Lynch MSI Cervelli T. Int J Mol Sciences Page 10
11 Platinum is Effective in Treating Cancers in Patients with BRCA1/2 Mutations Ovarian cancer patients with BRCA mutations have a higher cure rate In part due to higher sensitivity to platinum Breast cancer in gbrca carriers Platinum is effective: most data for TNBC Better than standard chemo? Platinum > docetaxel chemo (TNT trial) in gbrca+ carriers with TNBC Pancreatic cancer in gbrca carriers Improved survival with and sensitivity to platinum Alsop. K, et al. J Clin Oncol. 2012; Yang D, et al. JAMA. 2011; Reiss KA, et al. JCO Precision Oncol. 2018; Blair AB, et al. J Am Coll Surg. 2018; Smith AL, et al. JCO Precision Oncol. 2018; Byrski T, et al. Breast Cancer Res Treat. 2014; Tutt A, et al. SABCS Abstract S3-01. Pathways Mechanism of Action PARPis inhibit repair of single strand (SS) DNA breaks in a tumor Unrepaired SS breaks become DS breaks in a replicating tumor Cancers in gbrca carriers cannot repair DS DNA breaks Thus, PARPis lead to cell death in BRCA-associated cancers by creating more DS breaks in the tumor that cannot be repaired. Murai J, et al. Cancer Res Page 11
12 Pathways Mechanism of Action Inhib of PARP enzyme activity SSBs PARP trapping Persistent unrepaired SSBs PARPi PARP Trapping of PARP- DNA complexes Synthetic Lethality in HR deficient tumors e.g., BRCA+ tumor Lethality not restricted to HR deficiency SSB=single strand break Murai J, et al. Cancer Res Pathways DNA Damage Repair PARPi BRCA1/2 Platinum Lynch MSI Cervelli T. Int J Mol Sciences Page 12
13 PARP Inhibitor Synthetic Lethality in BRCA Breast Cancers PARPi BRCA1/2 Platinum Lynch MSI X X Cervelli T. Int J Mol Sciences PARPi FDA Approval Which Cancers, Which Setting? Ovarian Breast FDA Prescribing Information. Page 13
14 Current FDA Status of PARPis FDA-approved Olaparib Rucaparib Niraparib Not yet FDA-approved Veliparib Talazoparib FDA Prescribing FDA Prescribing Information; Information; Clinicaltrials.gov. PARPis Approved for Maintenance after First Recurrence in Platinum-sensitive OC For all ovarian cancer (BRCA mutation or not) Including both germline and somatic BRCA-mutated OC More effective if BRCA mutation Studies that led to approval Niraparib (NOVA, FDA approved) Olaparib (SOLO-2/Study-19, FDA approved)) Rucaparib (ARIEL-3, NOT yet FDA approved)) FDA Prescribing Information; Clinicaltrials.gov. FDA Prescribing Information; Coleman RL, et al. Lancet Page 14
15 ENGOT-OV16/NOVA Niraparib Maintenance Niraparib maintenance after achieving CR or PR in patients with platinum-sensitive, relapsed ovarian cancer Median PFS, mo Niraparib (n=234) Placebo (n=116) gbrca cohort Non-gBRCA cohort Non-gBRCA cohort with HRD HR Mirza MR, et al. N Engl J Med PARPis as Single Agents for Treatment of Recurrence (i.e., not maintenance) Olaparib December 19, 2014; accelerated approval gbrca mutation 3 prior lines Olaparib tablets: 300 mg PO BID Rucaparib December 19, 2016; accelerated approval Deleterious BRCA mutation (gbrca and/or sbrca) 2 prior lines Rucaparib tablets: 600 mg PO BID Swisher EM, et al. Lancet Oncol. 2017; Kaufman B, et al. J Clin Oncol. 2015; Page 15
16 Olaparib FDA Approval Breast Cancer January 12, 2018 gbrca+ metastatic HER2-neg breast cancer Prior chemo in (neo)adjuvant or metastatic setting OlympiAD (Olaparib) Phase III Trial gbrca+ Metastatic Breast Cancer HER2-negative metastatic breast cancer and germline BRCA1 or BRCA2 mutation N=302 R 2:1 Olaparib 300 mg PO BID Standard Chemo: MD choice Capecitabine or Vinorelbine or Eribulin Primary Endpoint PFS Robson M, et al. N Engl J Med Page 16
17 OlympiAD (Olaparib) Phase III Trial gbrca+ Metastatic Breast Cancer 3 month significant improvement in PFS Median PFS 7.0 vs 4.2 months; HR 0.58; P<0.001 No improvement in overall survival FDA approved Robson M, et al. N Engl J Med EMBRACA (Talazoparib) Study Design Patients with: locally advanced or metastatic HER2- negative breast cancer and germline BRCA1 or BRCA2 mutation N=431 R 2:1 Talazoparib 1 mg PO daily Standard Chemo: MD choice Capecitabine or Vinorelbine or Eribulin or Gemcitabine Primary Endpoint PFS Phase 3, international, open-label study randomized 431 patients in 16 countries and 145 sites Litton J, et al. SABCS Abstract GS6-07. Page 17
18 EMBRACA Talazoparib in BRCA+ MBC 3 month significant improvement in PFS Median PFS: 8.6 vs 5.6 mos; HR 0.54; P< No improvement in overall survival Not yet FDA approved MBC=metastatic breast cancer Litton J, et al. SABCS Abstract GS6-07. Updated NCCN Breast Cancer Guideline v Footnote suggests testing all treatment eligible patient population Patients with HER2-negative disease eligible for single-agent therapy are eligible for germline BRCA1/2 testing. Page 18
19 TO-PARP Trial PARPi in Prostate Cancer Olaparib worked in metastatic prostate cancer patients 14/16 (88%) response if mutations/biallelic loss in DNA repair gene, especially ATM, BRCA1/2 Responses with inherited and somatic mutations Mateo J, et al. N Engl J Med PARPis and Prostate Cancer Olaparib: FDA breakthrough therapy designation in castration resistant prostate cancer BRCA1/2 (germline or somatic) mutation ATM (germline or somatic) mutation Helleday T. Ann Oncol Page 19
20 Summary PARPi FDA Approvals Ovarian Cancer All patients: maintenance after first platinum-sensitive relapse g/s BRCA+: treatment for relapse if 2 prior chemo Breast Cancer gbrca+: metastatic HER2-negative, with prior chemotherapy g=germline; s=somatic FDA Prescribing Information. What, When, Who and How? Keeping Up with Genetic Testing Guidelines Justine Cooper Pickarski, MS, LGC University of Kentucky Markey Cancer Center Lexington, KY Page 20
21 Somatic Testing vs Germline Testing Somatic Identifies mutations in the tumor (i.e., acquired changes) Is performed on tumor tissue The patient has cancer The purpose is to identify treatment options and determine prognosis Is ordered by oncologist The patient is not often consented Germline Identifies mutations in the germline (i.e., mutations you are born with) Is performed on blood/saliva The patient may be unaffected The purpose is to identify patients with inherited cancer predisposition syndromes Is often ordered by GC, sometimes by oncologist, surgeon, PCP, etc. The patient often receives counseling Available Testing Technologies and Proper Interpretation of Results Tumor only Only the tumor tissue is analyzed Unable to filter out germline mutations Tumor normal Tumor tissue and normal tissue (i.e., blood) is analyzed May filter out germline mutations when reporting results Liquid biopsy Circulating tumor DNA in blood is analyzed May filter out germline mutations when reporting results Jones S, et al. Sci Transl Med. 2015; Page 21
22 Prostate Cancer Consensus Conference 2017 Confirmatory germline genetic testing for prostate cancer predisposition should occur for men with prostate tumor sequencing that shows mutations for the following cancer-risk genes: BRCA1/BRCA2 DNA MMR genes (MLH1, MSH2, MSH6, PMS2, EPCAM) HOXB13 ATM Giri VN, et al. J Clin Oncol. 2018; Richman S. Int J Oncol Page 22
23 ASCO Policy Statement ASCO supports the communication to patients of medically relevant incidental germline findings from somatic mutation profiling conducted in the clinical setting. Oncology providers should communicate the potential for incidental and secondary germline information to patients before conducting somatic mutation profiling and should review the potential benefits, limitations, and risks before testing. Robson ME, et al. J Clin Oncol Discussion Prior to Testing Risk group based on Pre-NGS probability Description of Pre-NGS groups High Strong family or personal history of malignancy, per current tumor-specific genetic counseling guidelines Ashkenazi Jewish heritage Intermediate May have family history of malignancy or other high risk features (e.g., very early age at diagnosis), but does not meet current guidelines for referral to genetic counseling/testing Low Unimpressive family history (either no known history of malignancy or remote, isolated cases) Recommendations to the oncologist before/after ordering NGS Emphasize the implications of NGS testing, including the possibility of identifying a somatic mutation that would be suspicious for germline potential Prior to testing: ask the patient about their preferences regarding disclosure of this information Prior to obtaining NGS results: strongly consider referral to a genetic counselor Discuss the implications of NGS testing and the possibility of identifying a somatic mutation that would be suspicious for germline potential Prior to testing: ask the patient about their preferences regarding disclosure of this information After NGS testing: use post-ngs risk to determine whether referral to genetic counselor and germline testing is warranted. When in doubt, discuss the case with a genetic counselor to clarify whether referral is recommended Briefly mention the implications of NGS testing and the rare possibility of identifying a somatic mutation that would be suspicious for germline potential Prior to testing: ask the patient about their preferences regarding disclosure of this information After NGS testing: use post-ngs risk to determine whether referral to genetic counselor and germline testing is warranted. When in doubt, discuss the case with a genetic counselor to clarify whether referral is recommended Catenacci D, et al. Int J Cancer Page 23
24 How Often are Germline Findings Identified in the Tumor? Meric-Bernstam F, et al. Ann Oncol advanced cancer patients offered tumor-normal sequencing with 202-gene panel (19 clinically actionable in germline) at MD Anderson 422/1000 (42%) had pathogenic somatic variant in one of 19 genes 43/1000 (4.3%) had a likely pathogenic germline variant identified Tumor types included breast, colon, brain, melanoma, sarcoma, ovary, and head and neck Schrader KA, et al. JAMA Oncol advanced cancer patients offered tumor-normal sequencing with MSK-IMPACT panel (341-gene panel) 198/1566 (12.6%) had pathogenic germline variant in cancer susceptibility gene Germline findings concordant with cancer type in only 81/198 (40.9%) cases Seifert BA, et al. Clin Cancer Res unselected cancer patients offered tumor-normal sequencing of 247 genes (36 genes strongly associated with hereditary cancer) at UNC 19/439 (4.3%) had pathogenic germline variant 12/19 (63%) were concordant with cancer type Suggestive of Germline Finding All BRCA1 and BRCA2 pathogenic variants regardless of tumor type (NCCN guideline) Founder mutations (i.e., MSH2 exon 1 6 deletion,tp53 R337H, CHEK2 1100delC) Uncommonly somatically mutated genes (i.e., MSH6, PALB2) Lynch HT, et al. JAMA. 2004; Tishkowitz A, Xia B. Cancer Res. 2010; Raymond VM, et al. J Natl Cancer Inst. 2015; Silva FC, et al. BMC Med Genet. 2014; NCCN Breast/Ovarian Genetic Assessment Guidelines v Page 24
25 Percentage of Somatic vs Germline Variants Meric-Bernstam F, et al. Ann Oncol Suggestive of Germline Finding All BRCA1 and BRCA2 pathogenic variants regardless of tumor type (NCCN guideline) Founder mutations (i.e., MSH2 exon 1 6 deletion, TP53 R337H, CHEK2 1100delC) Uncommonly somatically mutated genes (i.e., CHEK2, PALB2) Gene consistent with phenotype Same mutation detected in multiple primary tumors Underlying mutation pattern (i.e., hypermutated tumor) High mutant allele frequency (MAF) Lynch HT, et al. JAMA. 2004; Tishkowitz A, Xia B. Cancer Res. 2010; Raymond VM, et al. J Natl Cancer Inst. 2015; Silva FC, et al. BMC Med Genet. 2014; Li MM, et al. J Mol Diagn. 2017; NCCN Breast/Ovarian Genetic Assessment Guidelines v Page 25
26 Mutant Allele Frequency MAF can be suggestive of a germline mutation MAF >50% suggest loss of heterozygosity (LOH) Germline mutations in tumor suppressor genes often undergo LOH events High MAF also seen in normal course of tumor development without a germline mutation Do not use low MAF to rule OUT a germline mutation! Merajver SD, et al. Clin Cancer Res. 1995; Li MM, et al. J Mol Diagn Mutant Allele Frequencies AF=allelic frequency Meric-Bernstam F, et al. Ann Oncol Page 26
27 Refer if Tumor Testing is Normal? Regardless of tumor results, if the patient meets criteria for germline testing (NCCN guidelines), REFER! Large deletion in somatic can mask germline point mutation Somatic vs germline labs cover different areas of the genes Rearrangement not done on all genes Pathogenic variant in germline may not be considered pathogenic in tumor, therefore not reported or reported as VUS Testing is not completed for all clinically relevant genes VUS=variant of unknown significance Schrader KA, et al. JAMA Oncol. 2016; NCCN Breast/Ovarian Genetic Assessment Guidelines v Barriers and Clinical Challenges Insurance coverage Becoming less of an issue with lower patient-pay prices Single-site vs full panel Patient may have previously declined counseling/testing Patients often confused about germline vs somatic testing Sick patients Often need to be seen relatively quickly Everett JN, et al. J Genet Counsel Page 27
28 Abbreviations ADP adenosine diphosphate GC genetic counselor AF allelic frequency GWAS genome-wide association study ASCO American Society of Clinical Oncology HER2 human epidermal growth factor BER base excision repair receptor 2 BID twice daily HR hazard ratio; or homologous CR complete response recombination DDR DNA damage response HRD homologous repair deficiency DS double strand LOH loss of heterozygosity FA Fanconi anemia MAF mutant allele frequency FDA U.S. Food and Drug Administration MBC metastatic breast cancer gbrca germline BRCA MMR mismatch repair MSI microsatellite instability Abbreviations NCCN National Comprehensive Cancer Network NER nucleotide excision repair NGS next-generation sequencing NHEJ non-homologous end joining OC ovarian cancer OR odds ratio PARP poly (ADP-ribose) polymerase PARPi PARP inhibitor PCP primary care provider PFS progression-free survival PO by mouth PR partial response PRS polygenic risk scores RR relative risk RRSO risk-reducing salpingo-oophorectomy sbrca somatic BRCA SNP single-nucleotide polymorphism SS single strand SSB single strand break TNBC triple negative breast cancer VUS variant of unknown significance Page 28
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationModerator: Paula J. Anastasia RN, MN, AOCN Gyn-Onc Clinical Nurse Specialist Cedars-Sinai Medical Center Los Angeles, CA
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationPARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.
PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationOptimizing DNA Damage Response- Targeting Therapies: Focus on Genetic Testing and Counseling
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationGenetics & Precision Medicine Cancer Care
Genetics & Precision Medicine Cancer Care Johnathan M. Lancaster, MD PhD Chief Medical Officer Myriad Genetics Copyright 2015 Myriad Genetics, Inc., all rights reserved. www.myriad.com. Precision Medicine
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationManaging Moderate Penetrance
Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More informationCASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile.
CASE STUDY Mutation-Specific Testing: Eligibility for PARP Introduction Genetic testing is an emergent diagnostic technique that can provide specific and actionable inputs to the management of cancer therapy.
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationAbstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50
Abstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50 Garber JE 1, Tung NM 2, Elkin EP 3, Allen BA 3, Singh NA 3, Wenstrup R 3, Hartman AR 3,
More informationHereditary Cancer Update Strengthening Linkages Workshop April 22, 2017
Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,
More informationObjectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.
1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationGenetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel
Genetic counseling and testing Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau, honoraria, consultancy Astra
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationThe Role of genetic Testing for Inherited Prostate Cancer Risk
FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationObjectives. Case Study #1 1/28/14. A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice
A Collaborative Practice Approach to Genetic Testing in Cancer: Translating Science Into Clinical Practice Heather Hampel, MS, CGC Associate Director, Division of Human Genetics Professor, Department of
More informationRole of genetic testing in familial breast cancer outside of BRCA1 and BRCA2
Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationGENETIC TESTING FOR HEREDITARY CANCER
UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationModelling cancer risk predictions:clinical practice perspective.
Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationBRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY
BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationCorporate Medical Policy
Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More informationAdvanced Ovarian Carcinoma
Advanced Ovarian Carcinoma What is our standard of care? IV carbo/taxol IP platinum/taxane (what regimen?) IV carbo/taxol/bevacizumab + 12 months of Bev IV carbo + dose dense taxol Controversy between
More informationFamily Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool
Besides the BRCA genes, what else to consider in hereditary breast and ovarian cancer? Laurie M. Connors DNP, APNG, FNP-BC, AGN-BC Objectives Evaluate personal & family history to assess risk for hereditary
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationCASE STUDY. Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk. Introduction.
CASE STUDY Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk Introduction Germline cancer risk assessment tests are well-prescribed tests from Strand Life
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationInherited Cancer Genomics and Prevention:
Inherited Cancer Genomics and Prevention: How much cancer risk is inherited? Clinical utility of germline genetic testing in precision prevention and targeted therapy Kenneth Offit MD MPH Chief, Clinical
More informationGenetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
More informationDNA Damage Response analyst science event
DNA Damage Response analyst science event Mene Pangalos, EVP, Innovative Medicines & Early Development and Business Development Klaus Edvardsen, Vice President, Oncology Clinical, Global Medicines Development
More informationGenetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP
Genetics and Cancer Care Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP Faculty/Presenter Disclosure Faculty: Cynthia Forster-Gibson Relationships with commercial interests:
More informationThe Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine
The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationObjectives. Genetics in Cancer Treatment and Prevention. Genes
Objectives Genetics in Cancer Treatment and Prevention Cheryl LaFlore, ARNP, MSN, BC Understand how to integrate genetic and genomic information into oncology nursing practice Define the role of an oncology
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth
More informationHereditary Breast and Ovarian Cancers: Risk Management Recommendations. Objectives
Hereditary Breast and Ovarian Cancers: Risk Management Recommendations Tuya Pal, MD Moffitt Cancer Center Objectives 1 Identify genes associated with Hereditary Breast/Ovarian Cancer, including new and
More informationSHARSHERET. New Recommendations for Genetic Testing: How Do I Make Sense Of It All?
Sharsheret 2018 SHARSHERET New Recommendations for Genetic Testing: How Do I Make Sense Of It All? Wednesday, December 19, 2018 To listen to the presentation by phone: Dial: 1 (415) 655-0052 Access Code:
More informationTHE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES
THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES
More informationLearn your genetic risk for the most common hereditary cancers.
Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationGenetic Determinants, Risk Assessment and Management
Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon
More informationMP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)
More informationCarol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center
Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More information